Jarushka Naidoo
Beaumont RCSI Cancer Centre · Beaumont RCSI Cancer Centre, Beaumont Hospital · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jarushka Naidoo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:05 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07099027 · The Lung Health Check PilotRoyal College of Surgeons, Ireland · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT05673187 · Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance StatusETOP IBCSG Partners Foundation · active not recruiting · NSCLC Stage IV, KRAS P.G12C · study chair
- Ph2NCT04438382 · Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory PneumonitisECOG-ACRIN Cancer Research Group · terminated · Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis · principal investigator
- Ph2NCT03091478 · Pembrolizumab in Patients With Leptomeningeal DiseaseSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Patients With Leptomeningeal Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN NCORP Research BaseUG1CA189828 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL, Lynne I. Wagner · fiscal years 2014 to 2026Named on NCT04438382
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:05 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.N Engl J Med · 20181,689 citationsRCR 52.2
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.J Clin Oncol · 20221,268 citationsRCR 88.1
- Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.J Thorac Oncol · 2021388 citationsRCR 21.2
- Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.J Thorac Oncol · 202398 citationsRCR 6.6
- Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.J Immunother Cancer · 202455 citationsRCR 5.6
- Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.J Thorac Oncol · 201639 citationsRCR 1.3
- 8 citationsRCR 1.3